Magenta Therapeutics Provides Portfolio Update: Stem Cell Mobilization and Conditioning Programs Prioritized and Advancing Toward Clinical Milestones
— MGTA-145 first-line mobilization program to move into Phase 2 studies in autologous and allogeneic…